Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Christoph RölligBjörn SteffenChristoph SchliemannJan-Henrik MikeschNael AlakelRegina HerbstMathias HänelRichard NoppeneyMaher HanounMartin KaufmannBarbora WeinbergerováKerstin Schäfer-EckartTim SauerAndreas NeubauerAndreas BurchertClaudia D BaldusJolana MertováEdgar JostDirk NiemannJan NovákStefan W KrauseSebastian SchollAndreas HochhausGerhard HeldTomas SzotkowskiAndreas RankChristophe SchmidLars FranseckySabine KayserMarkus SchaichMichael KramerFrank FiebigAnnett HaakeJohannes ScheteligJan Moritz MiddekeFriedrich StölzelUwe PlatzbeckerChristian ThiedeCarsten Muller-TidowWolfgang E BerdelGerhard EhningerJiří MayerHubert ServeMartin BornhäuserPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.